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after 24h, Jagged1 and 2 genes were simultaneously silenced. Every 48h cells
were diluted and transfected again. Quantitative PCR reactions were carried
out on a 7500 Fast Real-time PCR system (Applied Biosystems) using the
Maxima™ SYBR Green/ROX qPCR Master Mix (Dasit).
Results: RNA interference for Jagged-1 and 2 in OPM-2 and U266 cells
resulted in the reduced expression of anti-apoptotic genes such as SDF-1alfa,
CXCR4, Bcl-XL, Bcl-2, Survivin and ABCC1. At the same time, MM cells with
reduced levels of Jagged-1 and 2 showed an increased sensivity to different
drugs commonly used in MM therapy such as Bortezomib, Mitoxantrone and
Melphalan. By co-culturing MM cell lines and BMSCs in the presence or the
absence of chemotherapeutic agents we observed that BMSCs were able to
protect MM cells from apoptosis. We investigated the underlying mechanism
showing that MM cells and BMSC interaction resulted in the activation of Notch
signaling in both cell types. MM cells-driven Notch signaling activation in
BMSCs resulted in the increased expression of soluble growth factors relevant
for MM cell growth and survival, such as SDF-1alfa and VEGF. On the other
side, BMSCs increased in MM cells the expression of several anti-apoptotic
genes, i.e. Bcl-XL, Bcl-2, Survivin and ABCC1. Interestingly, Jagged-1 and 2
silencing in MM cells could reverse all gene expression changes and BMSC
protective effect. Finally, the CXCR4 antagonist AMD3100 could partially
reverse the protective effect of BMSCs to drugs-induced apoptosis in MM cells,
suggesting that Jagged ligands deregulation observed in MM is necessary to
BM-promoted drug resistance by activating the SDF1alfa/CXCR4 chemokine
signaling.
Summary and Conclusion: The evidence that anti-Jagged-1 and 2 siRNAs
affect endogenous and BMSC-induced drug resistance in MM cells suggests
that a Jagged-directed approach could be effective in MM therapy alone or in
a combined treatment with commonly used drugs.
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Background: Multiple myeloma (MM) is a malignant plasma cells (PC) disorder
accounting for approximately 10% of hematologic cancers. Even though
advanced chemotherapeutic regimens have increased the median time of
survival to 5 years after diagnosis, myeloma remains incurable. Once
immortalized, the survival and proliferation of myeloma cells strictly depend on
a complex interaction with the bone marrow (BM) microenvironment, which is
mediated both by adhesion molecules and production of several cytokines,
especially interleukin-6 (IL-6). Following MM progression, at the stage of plasma
cell leukemia, the malignant PC acquires autonomous proliferative ability,
becomes indipendent on growth factors like IL-6 and is no longer confined in
the BM. Several recent evidences point to a possible role for Notch signaling
in mediating critical events in MM progression. The Notch pathway is highly
conserved and plays a crucial role in cell-fate decision, tissue patterning and
morphogenesis. Recently, Notch receptors and ligands have been shown to be
upregulated during MM progression and their signaling positively regulates cell
proliferation, drug resistance and BM infiltration.
Aims: The ability of Notch signaling to regulate proliferation and survival
pathways (i.e. NF-kB, AKT, Myc, and the same IL-6) prompted us to study if its
up-regulation during MM progression may play a role in the acquirement of IL-
6 independence. To this end we used two opposite approaches. Specifically,
we verified if Notch signaling upregulation in IL-6 dependent cell lines promotes
their independence and assessed if, upon Notch inihibition, IL-6 independent
MM cell lines lost self-sufficient proliferation.
Methods: Cell culture and cell growth analysis: HMCL CMA03, INA-6 and
XG-1 were maintained in complete RPMI-1640 medium supplemented with
10% V/V FBS and IL-6 10, 2.5 or 1 ng/mL, respectivetly. OPM2, CMA03/06 and
U266 cell lines were cultured in the same conditions without IL-6 addition. The
number and viability of cells were assessed by means of trypan blue exclusion
assay. The Notch inihibitor, DAPT, was added to the medium at the final
concentration of 50mM. Soluble Jagged1 was used at 5mg/mL.
Flow cytometry analysis: Apoptosys analysis was perfomed by AnnexinV-
FITC/Propidium Iodide staining. Cell cycle analysis was performed by
Propidium Iodide staining.
Real time-PCR: Quantitative PCR reactions were carried out using the
Maxima™ SYBR Green/ROX qPCR Master Mix.
Results: To evaluate if Notch pathway upregulation is involved in the
development of IL-6 independence in MM cells, we activated the Notch
signaling in three MM cell lines, CMA03, INA-6 and XG-1, strictly dependent
on IL-6. At this purpose, MM cells were cultured with the soluble form of the
Notch ligand Jagged1. We demonstrated that Jagged1 stimulation partially
rescued the reduced cell growth due to IL-6 withdrawal. On the other hand,
three different IL-6 independent cell lines, CMA03/06, OPM2 and U266, treated
with a gamma-secretase inhibitor (DAPT) which causes Notch pathway
blockade, displayed a significant decrease in cell growth. Remarkably, this
effect could be reverted by the addition of IL-6 in the culture medium. The
mechanisms underlying Notch-IL-6 crosstalking was partially investigated.
Preliminary results indicate that Notch signalling is required for MM cell
autonomous IL-6 production.
Summary and Conclusion: The present results suggest that Notch pathway
activation may contribute to the transition from IL-6-dependent to IL-6-
independent MM cell growth. Furthermore, the inhibition of the Notch patwhay
may lead to a decrease in MM cells proliferation in part due to the reduction of
IL-6 expression. Even though studies are necessary to identify further
mechanisms of IL-6 independence possibly involving other Notch downstrem
pathways, these preliminary results support the rationale for a Notch-directed
approach in plasma cell dyscrasias.
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Background: Cell death and autophagy are the main cellular processes
involved in the regulation of bone remodeling by osteocytes. Recently we have
demonstrated that an increased osteocyte death is involved in multiple
myeloma (MM)-induced osteolysis through the upregulation of osteoclast
recruitment.
Aims: Because proteasome inhibitors including Bortezomib (BOR) are known
to be able to target osteoblasts in this study we have investigated the potential
effect of these drugs on osteocytes and their cell death and autophagy.
Methods: Firstly the effect of the proteasome inhibitors BOR and MG262 on
osteocyte viability was evaluated in vitro in murine osteocytic cell line MLO-Y4
and in the human pre-osteocytic one HOB-01. Both cell lines were co-coltured
for 48 hours in the presence or absence of the human myeloma cell lines
(HMCLs) RPMI8226 and JJN3, placed in a transwell insert in the presence or
the absence of BOR or MG262. Moreover the effect of proteasome inhibitors
on dexamethasone (DEX)-induced MLO-Y4 death, obtained at high doses (10-
5-10-6M), was checked in combination with PTH(1-34). To evaluate the
presence of autophagy and apoptosis in osteocytes, we checked the
expression of both autophagic marker LC3 and apoptotic marker APAF-1 by
confocal microscopy in the co-colture system with MLO-Y4 and RPMI-8226.
Finally we performed a retrospective histological evaluation on bone biopsies
of a cohort of 31 newly diagnosis MM underwent to different treatments
including BOR-based regimen. Bone biopsies were obtained at the diagnosis
and after an average time of 12 months of treatment. Osteocyte viability was
evaluated in a total of 500 lacunae per histological sections.
Results: The in vitro treatment with BOR or MG262 significantly blunted MLO-
Y4 and HOB-01 cell death. Similarly, DEX-induced MLO-Y4 death was reduced
by proteasome inhibitors. Interestingly, we found that both proteasome
inhibitors potentiated the PTH (1-34) short-term effects on DEX-induced
osteocyte death. Prevalence of autophagic cell death compared to apoptosis
was observed in this system. In line with these data, we showed that neither
the HMCLs nor treatment with DEX increase the apoptotic death and caspase
3 activation in both MLO-Y4 and HOB-01 cell lines. BOR treatment increased
the basal level of LC3 indicating a pro-survival and protective function of
autophagy against the BOR-induce stress. On the contrary, when the cells
undergo to a stronger stress such as in the presence of HMCLs or by treatment
with high dose of DEX we found that both proteasome inhibitors blocked
autophagic cell death in osteocytes. In the in vivo study we found a significant
increase of the number of viable osteocytes in MM patients treated with BOR-
based regimen as compared to those treated without BOR (% median increase:
+6% vs. +1.30%; p=0.017). Patients treated with BOR alone showed the
highest increase of osteocyte viability, as compared to those either treated
without BOR (+11.6% vs. +1.3%, p=0.0019) or treated with BOR plus DEX
(+11.6% vs. +4.4%, p=0.01). On the other hand, any significant difference was
not observed in patients treated with Thalidomide (THAL) or Immunomodulatory
drugs (IMiDs) than in those untreated with these drugs (p=0.7). A multiple
regression non-parametric analysis showed that BOR had a significant positive
impact on osteocyte viability (p=0.042) whereas THAL/IMiDs as well as
Zoledronic acid (ZOL) treatments have not (p=0.2). BOR also counterbalanced
the negative effect of DEX treatment (p=0.035).
Summary and Conclusion: Our data suggest that proteasome inhibitors
blunted osteocyte cell death induced by MM cells and DEX through the
modulation of the autophagy and potentiated the effect of PTH. Overall our in
vitro and in vivo data support the use of BOR to improve bone integrity in MM
patients.
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